← Back to Search

Mitochondrial-targeted antioxidant

MitoQ Supplementation for Cardiovascular Health

N/A

Waitlist Available

Led By Shauna Runchey, MD

Research Sponsored by University of Colorado, Denver

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

50 - 75 years of age

Be older than 18 years old

Must not have

History of cancer

History of cardiovascular disease

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline and 4 weeks

Summary

This trial will see if an antioxidant called Mitoquinone can help improve mitochondrial function, heart function, and blood vessel function.

Who is the study for?

This trial is for healthy men and women aged 50-75 who are not very active, don't smoke, and aren't taking antioxidants, steroids or anti-inflammatory meds. They shouldn't have had cancer, cardiovascular disease or be on hormone therapy.

What is being tested?

The study tests if MitoQ (a targeted antioxidant) can improve heart's mitochondrial function and blood vessel health in participants. They'll take MitoQ first then a placebo, or vice versa to compare effects.

What are the potential side effects?

Potential side effects of MitoQ may include allergic reactions, gastrointestinal discomforts such as nausea or diarrhea, headache, fatigue but specific side effects will be monitored during the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 50 and 75 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have had cancer in the past.

Select...

I have a history of heart disease.

Select...

I am willing and able to take MitoQ supplement.

Select...

I am currently on sex hormone therapy.

Select...

I am currently taking antioxidant vitamins, corticosteroids, or anti-inflammatory medications.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline and 4 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline and 4 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 4 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Changes in diastolic function

Secondary study objectives

Changes in arterial stiffness

Changes in arterial vascular coupling

Changes in brachial artery flow-mediated dilation

+2 more

Trial Design

2Treatment groups

Experimental Treatment

Group I: B: Placebo then 'MITOQUINOL MESYLATE'Experimental Treatment1 Intervention

Placebo capsule administered twice daily for 4 weeks followed by a washout period, then 'MITOQUINOL MESYLATE' administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'

Group II: A: 'MITOQUINOL MESYLATE then placeboExperimental Treatment1 Intervention

'MITOQUINOL MESYLATE' administered twice daily for 4 weeks followed by a washout, then placebo capsule administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'.

0 / 6Eligibility criteria met